Cholinesterase inhibitors, such as donepezil and rivastigmine, have been investigated for their potential role in the treatment of POD, based on the cholinergic deficiency hypothesis.[152] These medications have been shown to improve cognitive function and reduce the severity of delirium in patients with Alzheimer’s disease.[153] However, the evidence for their efficacy in the treatment of POD is limited, and further research is needed to establish their role in the management of this condition.[142]. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.